Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “therapy”

782 pharma patents match "therapy" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 782
Index total 30,257
Page 10 / 33

Quick answer

This filtered view shows 782 pharmaceutical patents matching "therapy" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

782 results for “therapy” · 30,257 patents in full index Clear search

  1. US 11376324

    Sting activating nanovaccine for immunotherapy

    The Board of Regents of the University of Texas System · Granted Jul 5, 2022 · Expires Jun 30, 2042

    granted
  2. US 11365250

    Compositions and methods for cancer therapy

    The Board of Regents of the University of Texas System · Granted Jun 21, 2022 · Expires Jun 16, 2042

    granted
  3. US 11357842

    PD-L1 targeting DNA vaccine for cancer immunotherapy

    Vaximm AG · Granted Jun 14, 2022 · Expires Jun 9, 2042

    granted
  4. US 11352639

    Gene therapy based on vector VTVAF17

    OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTJU “ALLEL TSENTR INNOVATSIONNYKH BIOTEKHNOLOGY” · Granted Jun 7, 2022 · Expires Jun 2, 2042

    granted
  5. US 11344579

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted May 31, 2022 · Expires May 26, 2042

    granted
  6. US 11337998

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted May 24, 2022 · Expires May 19, 2042

    granted
  7. US 11338013

    Combination therapy for C3 inhibition

    Apellis Pharmaceuticals, Inc. · Granted May 24, 2022 · Expires May 19, 2042

    granted
  8. US 11324813

    Indoleamine 2,3-dioxygenase based immunotherapy

    IO Biotech ApS · Granted May 10, 2022 · Expires May 5, 2042

    granted
  9. US 11324811

    Optimization of enzyme replacement therapy for treatment of homocystinuria

    The Regents of the University of Colorado, a Body Corporate · Granted May 10, 2022 · Expires May 5, 2042

    granted
  10. US 11318164

    Immunotherapeutic treatment method using an interleukin-2 receptor beta-selective agonist in combination with adoptive cell transfer therapy

    Nektar Therapeutics · Granted May 3, 2022 · Expires Apr 28, 2042

    granted
  11. US 11304979

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Apr 19, 2022 · Expires Apr 14, 2042

    granted
  12. US 11304996

    Yeast-based immunotherapy and type I interferon sensitivity

    The Regents of the University of Colorado, a Body Corporate · Granted Apr 19, 2022 · Expires Apr 14, 2042

    granted
  13. US 11291667

    Combination therapy involving diaryl macrocyclic compounds

    TURNING POINT THERAPEUTICS, INC. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  14. US 11291687

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  15. US 11285194

    Combination immunotherapy approach for treatment of cancer

    Calidi Biotherapeutics, Inc. · Granted Mar 29, 2022 · Expires Mar 24, 2042

    granted
  16. US 11286528

    Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy

    BIOVERATIV THERAPEUTICS INC. · Granted Mar 29, 2022 · Expires Mar 24, 2042

    granted
  17. US 11278592

    Methods and compositions for TUSC2 immunotherapy

    The Board of Regents of the University of Texas System · Granted Mar 22, 2022 · Expires Mar 17, 2042

    granted
  18. US 11273180

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted
  19. US 11273181

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted
  20. US 11266692

    Intracellular genomic transplant and methods of therapy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 8, 2022 · Expires Mar 3, 2042

    granted
  21. US 11254731

    Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A

    Takeda Pharmaceutical Company Limited · Granted Feb 22, 2022 · Expires Feb 17, 2042

    granted
  22. US 11254913

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Feb 22, 2022 · Expires Feb 17, 2042

    granted
  23. US 11246950

    Combination cancer immunotherapy with pentaaza macrocyclic ring complex

    Galera Labs, LLC · Granted Feb 15, 2022 · Expires Feb 10, 2042

    granted
  24. US 11241456

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted